These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 24954007)

  • 1. Selective chemical modulation of gene transcription favors oligodendrocyte lineage progression.
    Gacias M; Gerona-Navarro G; Plotnikov AN; Zhang G; Zeng L; Kaur J; Moy G; Rusinova E; Rodriguez Y; Matikainen B; Vincek A; Joshua J; Casaccia P; Zhou MM
    Chem Biol; 2014 Jul; 21(7):841-854. PubMed ID: 24954007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonequivalent response to bromodomain-targeting BET inhibitors in oligodendrocyte cell fate decision.
    Chiang CM
    Chem Biol; 2014 Jul; 21(7):804-6. PubMed ID: 25036774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolically Derived Lysine Acylations and Neighboring Modifications Tune the Binding of the BET Bromodomains to Histone H4.
    Olp MD; Zhu N; Smith BC
    Biochemistry; 2017 Oct; 56(41):5485-5495. PubMed ID: 28945351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent and selective bivalent inhibitors of BET bromodomains.
    Waring MJ; Chen H; Rabow AA; Walker G; Bobby R; Boiko S; Bradbury RH; Callis R; Clark E; Dale I; Daniels DL; Dulak A; Flavell L; Holdgate G; Jowitt TA; Kikhney A; McAlister M; Méndez J; Ogg D; Patel J; Petteruti P; Robb GR; Robers MB; Saif S; Stratton N; Svergun DI; Wang W; Whittaker D; Wilson DM; Yao Y
    Nat Chem Biol; 2016 Dec; 12(12):1097-1104. PubMed ID: 27775716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.
    Romero FA; Taylor AM; Crawford TD; Tsui V; Côté A; Magnuson S
    J Med Chem; 2016 Feb; 59(4):1271-98. PubMed ID: 26572217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites.
    Olp MD; Sprague DJ; Goetz CJ; Kathman SG; Wynia-Smith SL; Shishodia S; Summers SB; Xu Z; Statsyuk AV; Smith BC
    ACS Chem Biol; 2020 Apr; 15(4):1036-1049. PubMed ID: 32149490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The bromodomain: from epigenome reader to druggable target.
    Sanchez R; Meslamani J; Zhou MM
    Biochim Biophys Acta; 2014 Aug; 1839(8):676-85. PubMed ID: 24686119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains.
    Zhang G; Plotnikov AN; Rusinova E; Shen T; Morohashi K; Joshua J; Zeng L; Mujtaba S; Ohlmeyer M; Zhou MM
    J Med Chem; 2013 Nov; 56(22):9251-64. PubMed ID: 24144283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition.
    Theodoulou NH; Bamborough P; Bannister AJ; Becher I; Bit RA; Che KH; Chung CW; Dittmann A; Drewes G; Drewry DH; Gordon L; Grandi P; Leveridge M; Lindon M; Michon AM; Molnar J; Robson SC; Tomkinson NC; Kouzarides T; Prinjha RK; Humphreys PG
    J Med Chem; 2016 Feb; 59(4):1425-39. PubMed ID: 25856009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors.
    Ember SW; Zhu JY; Olesen SH; Martin MP; Becker A; Berndt N; Georg GI; Schönbrunn E
    ACS Chem Biol; 2014 May; 9(5):1160-71. PubMed ID: 24568369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule inhibitors of bromodomain-acetyl-lysine interactions.
    Brand M; Measures AR; Wilson BG; Cortopassi WA; Alexander R; Höss M; Hewings DS; Rooney TP; Paton RS; Conway SJ
    ACS Chem Biol; 2015 Jan; 10(1):22-39. PubMed ID: 25549280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bromodomain and extraterminal inhibitors block the Epstein-Barr virus lytic cycle at two distinct steps.
    Keck KM; Moquin SA; He A; Fernandez SG; Somberg JJ; Liu SM; Martinez DM; Miranda JL
    J Biol Chem; 2017 Aug; 292(32):13284-13295. PubMed ID: 28588024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of BET bromodomains.
    Filippakopoulos P; Qi J; Picaud S; Shen Y; Smith WB; Fedorov O; Morse EM; Keates T; Hickman TT; Felletar I; Philpott M; Munro S; McKeown MR; Wang Y; Christie AL; West N; Cameron MJ; Schwartz B; Heightman TD; La Thangue N; French CA; Wiest O; Kung AL; Knapp S; Bradner JE
    Nature; 2010 Dec; 468(7327):1067-73. PubMed ID: 20871596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase activity is necessary for oligodendrocyte lineage progression.
    Marin-Husstege M; Muggironi M; Liu A; Casaccia-Bonnefil P
    J Neurosci; 2002 Dec; 22(23):10333-45. PubMed ID: 12451133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
    Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
    Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bromodomains and their pharmacological inhibitors.
    Gallenkamp D; Gelato KA; Haendler B; Weinmann H
    ChemMedChem; 2014 Mar; 9(3):438-64. PubMed ID: 24497428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk.
    Sdelci S; Lardeau CH; Tallant C; Klepsch F; Klaiber B; Bennett J; Rathert P; Schuster M; Penz T; Fedorov O; Superti-Furga G; Bock C; Zuber J; Huber KV; Knapp S; Müller S; Kubicek S
    Nat Chem Biol; 2016 Jul; 12(7):504-10. PubMed ID: 27159579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
    Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polybromo-1-bromodomains bind histone H3 at specific acetyl-lysine positions.
    Chandrasekaran R; Thompson M
    Biochem Biophys Res Commun; 2007 Apr; 355(3):661-6. PubMed ID: 17320048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.